The clinical practice guideline for the management of amyotrophic lateral sclerosis in Japan-update 2023
- PMID: 38522911
- DOI: 10.5692/clinicalneurol.cn-001946
The clinical practice guideline for the management of amyotrophic lateral sclerosis in Japan-update 2023
Abstract
Amyotrophic lateral sclerosis (ALS) is an adult-onset intractable motor neuron disease characterized by selective degeneration of cortical neurons in the frontotemporal lobe and motor neurons in the brainstem and spinal cord. Impairment of these neural networks causes progressive muscle atrophy and weakness that spreads throughout the body, resulting in life-threatening bulbar palsy and respiratory muscle paralysis. However, no therapeutic strategy has yet been established to halt ALS progression. Although evidence for clinical practice in ALS remains insufficient, novel research findings have steadily accumulated in recent years. To provide updated evidence-based or expert consensus recommendations for the diagnosis and management of ALS, the ALS Clinical Practice Guideline Development Committee, approved by the Japanese Society of Neurology, revised and published the Japanese clinical practice guidelines for the management of ALS in 2023. In this guideline, disease-modifying therapies that have accumulated evidence from randomized controlled trials were defined as "Clinical Questions," in which the level of evidence was determined by systematic reviews. In contrast, "Questions and Answers" were defined as issues of clinically important but insufficient evidence, according to reports of a small number of cases, observational studies, and expert opinions. Based on a literature search performed in February 2022, recommendations were reached by consensus, determined by an independent panel, reviewed by external reviewers, and submitted for public comments by Japanese Society of Neurology members before publication. In this article, we summarize the revised Japanese guidelines for ALS, highlighting the regional and cultural diversity of care processes and decision-making. The guidelines cover a broad range of essential topics such as etiology, diagnostic criteria, disease monitoring and treatments, management of symptoms, respiration, rehabilitation, nutrition, metabolism, patient instructions, and various types of care support. We believe that this summary will help improve the daily clinical practice for individuals living with ALS and their caregivers.
Keywords: ALS; amyotrophic lateral sclerosis; guideline; motor neuron disease; systematic review.
Similar articles
-
Management of amyotrophic lateral sclerosis in clinical practice: Results of the expert consensus using the Delphi methodology.Rev Neurol (Paris). 2023 Dec;179(10):1134-1144. doi: 10.1016/j.neurol.2023.07.011. Epub 2023 Oct 10. Rev Neurol (Paris). 2023. PMID: 37827930
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD).Eur J Neurol. 2024 Jun;31(6):e16264. doi: 10.1111/ene.16264. Epub 2024 Mar 12. Eur J Neurol. 2024. PMID: 38470068 Free PMC article.
-
An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe.Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):88-97. doi: 10.1080/21678421.2017.1361445. Amyotroph Lateral Scler Frontotemporal Degener. 2017. PMID: 28872912 Review.
-
Cognitive and behavioural impairment in amyotrophic lateral sclerosis: A landmark of the disease? A mini review of longitudinal studies.Neurosci Lett. 2021 May 29;754:135898. doi: 10.1016/j.neulet.2021.135898. Epub 2021 Apr 15. Neurosci Lett. 2021. PMID: 33862143 Review.
Cited by
-
Evidence-Based Nutritional Recommendations for Maintaining or Restoring Nutritional Status in Patients with Amyotrophic Lateral Sclerosis: A Systematic Review.Nutrients. 2025 Feb 24;17(5):782. doi: 10.3390/nu17050782. Nutrients. 2025. PMID: 40077653 Free PMC article.
-
Improved Pharyngeal Contraction and Oral Intake Status After Modified Central-Part Laryngectomy for Late-Stage ALS.Otolaryngol Head Neck Surg. 2025 Jul;173(1):154-161. doi: 10.1002/ohn.1229. Epub 2025 Mar 19. Otolaryngol Head Neck Surg. 2025. PMID: 40105438 Free PMC article.
-
Effects of telerehabilitation on physical function and activities of daily living in patients with amyotrophic lateral sclerosis: a scoping review.J Phys Ther Sci. 2025 Aug;37(8):427-434. doi: 10.1589/jpts.37.427. Epub 2025 Aug 1. J Phys Ther Sci. 2025. PMID: 40757018 Free PMC article. Review.
-
Adverse events reporting of edaravone: a real-world analysis from FAERS database.Sci Rep. 2025 Mar 9;15(1):8148. doi: 10.1038/s41598-025-92605-5. Sci Rep. 2025. PMID: 40059194 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous